Liquid biopsies for hepatocellular carcinoma

Ying Hsiu Su, Amy Kim, Surbhi Jain

Research output: Contribution to journalReview article

Abstract

Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.

Original languageEnglish (US)
Pages (from-to)84-97
Number of pages14
JournalTranslational Research
Volume201
DOIs
StatePublished - Nov 1 2018

Fingerprint

Biopsy
Hepatocellular Carcinoma
Untranslated RNA
Methylation
Body fluids
Liquids
Biomarkers
Tumors
Screening
Cells
Circulating Neoplastic Cells
Body Fluids
Cause of Death
Survival Rate
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical
  • Physiology (medical)

Cite this

Liquid biopsies for hepatocellular carcinoma. / Su, Ying Hsiu; Kim, Amy; Jain, Surbhi.

In: Translational Research, Vol. 201, 01.11.2018, p. 84-97.

Research output: Contribution to journalReview article

Su, Ying Hsiu ; Kim, Amy ; Jain, Surbhi. / Liquid biopsies for hepatocellular carcinoma. In: Translational Research. 2018 ; Vol. 201. pp. 84-97.
@article{ae9b16bdb341487a9db6fb85a808443c,
title = "Liquid biopsies for hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4{\%} of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.",
author = "Su, {Ying Hsiu} and Amy Kim and Surbhi Jain",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.trsl.2018.07.001",
language = "English (US)",
volume = "201",
pages = "84--97",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Liquid biopsies for hepatocellular carcinoma

AU - Su, Ying Hsiu

AU - Kim, Amy

AU - Jain, Surbhi

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.

AB - Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.

UR - http://www.scopus.com/inward/record.url?scp=85050848942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050848942&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2018.07.001

DO - 10.1016/j.trsl.2018.07.001

M3 - Review article

VL - 201

SP - 84

EP - 97

JO - Translational Research

JF - Translational Research

SN - 1931-5244

ER -